

# (±) -Ibipinabant

## Catalog No: tcsc6430



### Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



### Specifications

---

**CAS No:**

362519-49-1

**Formula:**

$C_{23}H_{20}Cl_2N_4O_2S$

**Pathway:**

GPCR/G Protein

**Target:**

Cannabinoid Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 31$  mg/mL (63.60 mM)

**Alternative Names:**

(±)-SLV319;(±)-BMS6462

**Observed Molecular Weight:**

487.4


## Product Description

(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (**CB-1**) receptor antagonist with an **IC<sub>50</sub>** of 22 nM.

IC50 & Target: IC50: 22 nM (CB-1)<sup>[1]</sup>; Ki: 7.8 nM (CB-1)<sup>[2]</sup>

**In Vitro:** Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Ibipinabant is a new, potent [ $K_i$  (CB1)=7.8 nM] and selective [ $K_i$  (CB2)=7.943 nM] CB1 antagonist [pA<sub>2</sub> for arachidonic acid release in CHO cells=9.9] with *in vitro* pharmacological characteristics similar to rimonabant including inverse agonism and brain penetrance<sup>[3]</sup>.

**In Vivo:** (±)-Ibipinabant ((±)-SLV319) (3 mg/kg) reduces unfasted glucose to a significantly greater degree than rimonabant at the same dose on days 17, 28 and 38. Chronic treatment with (±)-Ibipinabant ((±)-SLV319) significantly attenuates the progression of diabetes in ZDF rats, blunting the increase in blood glucose and HbA<sub>1c</sub> over time. Ibipinabant also reduces the hyperinsulinemia apparent at 6-8 weeks of age and attenuates the dramatic reduction in insulin levels observed 1-2 weeks later<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!